Neoadjuvant peptide receptor radionuclide therapy for an inoperable neuroendocrine pancreatic tumor.

Abstract

Pancreatic endocrine tumors are rare but are among the most common neuroendocrine neoplasms of the abdomen. At diagnosis many of them are already advanced and difficult to treat. We report on an initially inoperable malignant pancreatic endocrine tumor in a 33-year-old woman, who received neoadjuvant peptide receptor radionuclide therapy (PRRT) as first-line treatment. This resulted in a significant downstaging of the tumor and allowed its subsequent complete surgical removal. Follow-up for eighteen months revealed a complete remission. This is the first report on neoadjuvant PRRT in a neuroendocrine neoplasm with subsequent successful complete resection.

• Authors: Daniel Kaemmerer, Vikas Prasad, Wolfgang Daffner, Dieter Hörsch, Günter Klöppel, Merten Hommann, Richard P Baum
• Journal: World journal of gastroenterology (World J Gastroenterol) Vol. 15 Issue 46 Pg. 5867-70 (Dec 14 2009) ISSN: 2219-2840 [Electronic] United States
• PMID: 19998512 (Publication Type: Case Reports, Journal Article)

Chemical References

• Radioisotopes
• Receptors, Peptide

Topics

• Adult
• Combined Modality Therapy
• Female
• Humans
• Lymph Nodes (pathology)
• Lymphatic Metastasis (pathology)
• Neoadjuvant Therapy (methods)
• Neuroendocrine Tumors (pathology, radiotherapy, surgery)
• Pancreatic Neoplasms (pathology, radiotherapy, surgery)
• Radioisotopes (therapeutic use)
• Receptors, Peptide (metabolism)
• Treatment Outcome